Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of geniposide in preparation of anti-pulmonary fibrosis drugs

A technology of geniposide and pulmonary fibrosis, which is applied in the field of biomedicine, can solve the problems that no one has reported the application of geniposide in the treatment of pulmonary fibrosis, and achieve the purpose of overcoming liver toxicity, improving collagen fiber deposition, and reducing hydroxyprophylaxis. The effect of amino acid content

Inactive Publication Date: 2020-01-10
KUNMING MEDICAL UNIVERSITY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no one has reported the application of geniposide in the treatment of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of geniposide in preparation of anti-pulmonary fibrosis drugs
  • Application of geniposide in preparation of anti-pulmonary fibrosis drugs
  • Application of geniposide in preparation of anti-pulmonary fibrosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] 1. Materials and methods

[0026] 1.1 Drug preparation

[0027] Extraction and separation of geniposide: crush 10 kilograms of gardenia fruits and soak them in 95% ethanol three times, each time for 12 hours, and filter; combine the ethanol extracts, recover the ethanol from the aluminum peroxide column, and separate the ethanol through silica gel column chromatography. Elute with chloroform, chloroform-ethanol (9:1), chloroform-ethanol (8:2), and ethanol; 500 g of geniposide crystals were obtained from the chloroform-ethanol eluted part with a purity of >98%.

[0028] Preparation of geniposide injection: Accurately weigh 200 mg of geniposide with a microanalytical balance, dissolve in 20 ml of sterile normal saline, mix well, filter and sterilize with a 0.22 μm microporous membrane, and pack in sterile in the test tube.

[0029] 1.2 Animal Treatment and Experimental Protocol

[0030] A total of 98 Kunming adult male SPF mice (7 weeks old, 20±2g, Kunming Medical Univ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of geniposide in preparation of anti-pulmonary fibrosis drugs, and belongs to the technical field of biological medicines. Research finds that the geniposide cansignificantly improve the degree of pulmonary fibrosis and delay the development process of pulmonary fibrosis, and is small in side effect and good in safety; and finds that the anti-pulmonary fibrosis action mechanism of the geniposide is related to inhibition of a TGF-beta1-Smad2 / 3 signal path and a TGF-beta1-p38MAPK signal path. The invention lays a powerful theoretical foundation and experimental basis for further development of the anti-pulmonary fibrosis effect of the geniposide.

Description

technical field [0001] The invention relates to the application of geniposide in the preparation of anti-pulmonary fibrosis drugs, belonging to the technical field of biomedicine. Background technique [0002] Pulmonary fibrosis (PF) is a progressive interstitial lung disease caused by a variety of causes, leading to the destruction of alveolar structure, reduced lung compliance, interrupted gas exchange, and eventually respiratory failure and death. Of note, the global incidence of PF appears to be increasing over time, conservatively estimated at 3-9 per 100,000 per year, with a median survival of only 2-4 years after diagnosis . The clinical manifestations of patients with pulmonary fibrosis are mainly dry cough, exertional dyspnea and overall progressive deterioration of the patient's quality of life. During the past decade, the understanding of the pathogenesis and management of PF has changed, and two drugs (pirfenidone and nintedanib) have been marketed and used cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P11/00
CPCA61K31/7048A61P11/00
Inventor 张旋邹澄王应霞成梦群尹健彬皮娜
Owner KUNMING MEDICAL UNIVERSITY